Advances in Aurora kinase inhibitor patents

Mohane Selvaraj Coumar, Chun-Hei Cheung, Jang-Yang Chang, Hsing Pang Hsieh

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Background: Aurora-A, Aurora-B and Aurora-C, members of serine/threonine kinase family, play an important role in mitosis. They are essential for spindle assembly, centrosome maturation, chromosomal segregation and cytokinesis during mitosis. Abnormalities in the mitotic process as a result of overexpression/amplification of Aurora kinase have been linked to genomic instability leading to tumorigenesis. Hence, the use of Aurora kinase small-molecule inhibitors as a potential molecular-targeted therapeutic intervention for cancer is being pursued. Objective: A number of reviews focus on the biology of Aurora kinase; a few focus on the medicinal chemistry aspect of Aurora kinase inhibitor development. Here, we review the medicinal chemistry aspect of Aurora kinase inhibitors, with a particular emphasis on the patent literature. Method: The Scifinder® and Delphion® databases were used to search the literature for Aurora kinase inhibitors. Approximately 150 patents and 700 journal references are available, most of them published in the last 5 years. Conclusion/results: Analysis of the literature reveals three common strategies utilized by different groups in developing Aurora kinase inhibitors. These are discussed in detail and could be of use to medicinal chemists in laying out new strategies for developing novel Aurora kinase inhibitors.

Original languageEnglish
Pages (from-to)321-356
Number of pages36
JournalExpert Opinion on Therapeutic Patents
Volume19
Issue number3
DOIs
Publication statusPublished - 2009 Mar 1

Fingerprint

Aurora Kinases
Patents
Pharmaceutical Chemistry
Mitosis
Literature
Centrosome
Cytokinesis
Genomic Instability
Protein-Serine-Threonine Kinases
Carcinogenesis
Databases

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

Coumar, Mohane Selvaraj ; Cheung, Chun-Hei ; Chang, Jang-Yang ; Hsieh, Hsing Pang. / Advances in Aurora kinase inhibitor patents. In: Expert Opinion on Therapeutic Patents. 2009 ; Vol. 19, No. 3. pp. 321-356.
@article{e5dbb44bf3e545b4aa16c2ed6500406c,
title = "Advances in Aurora kinase inhibitor patents",
abstract = "Background: Aurora-A, Aurora-B and Aurora-C, members of serine/threonine kinase family, play an important role in mitosis. They are essential for spindle assembly, centrosome maturation, chromosomal segregation and cytokinesis during mitosis. Abnormalities in the mitotic process as a result of overexpression/amplification of Aurora kinase have been linked to genomic instability leading to tumorigenesis. Hence, the use of Aurora kinase small-molecule inhibitors as a potential molecular-targeted therapeutic intervention for cancer is being pursued. Objective: A number of reviews focus on the biology of Aurora kinase; a few focus on the medicinal chemistry aspect of Aurora kinase inhibitor development. Here, we review the medicinal chemistry aspect of Aurora kinase inhibitors, with a particular emphasis on the patent literature. Method: The Scifinder{\circledR} and Delphion{\circledR} databases were used to search the literature for Aurora kinase inhibitors. Approximately 150 patents and 700 journal references are available, most of them published in the last 5 years. Conclusion/results: Analysis of the literature reveals three common strategies utilized by different groups in developing Aurora kinase inhibitors. These are discussed in detail and could be of use to medicinal chemists in laying out new strategies for developing novel Aurora kinase inhibitors.",
author = "Coumar, {Mohane Selvaraj} and Chun-Hei Cheung and Jang-Yang Chang and Hsieh, {Hsing Pang}",
year = "2009",
month = "3",
day = "1",
doi = "10.1517/13543770802646949",
language = "English",
volume = "19",
pages = "321--356",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "3",

}

Advances in Aurora kinase inhibitor patents. / Coumar, Mohane Selvaraj; Cheung, Chun-Hei; Chang, Jang-Yang; Hsieh, Hsing Pang.

In: Expert Opinion on Therapeutic Patents, Vol. 19, No. 3, 01.03.2009, p. 321-356.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Advances in Aurora kinase inhibitor patents

AU - Coumar, Mohane Selvaraj

AU - Cheung, Chun-Hei

AU - Chang, Jang-Yang

AU - Hsieh, Hsing Pang

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Background: Aurora-A, Aurora-B and Aurora-C, members of serine/threonine kinase family, play an important role in mitosis. They are essential for spindle assembly, centrosome maturation, chromosomal segregation and cytokinesis during mitosis. Abnormalities in the mitotic process as a result of overexpression/amplification of Aurora kinase have been linked to genomic instability leading to tumorigenesis. Hence, the use of Aurora kinase small-molecule inhibitors as a potential molecular-targeted therapeutic intervention for cancer is being pursued. Objective: A number of reviews focus on the biology of Aurora kinase; a few focus on the medicinal chemistry aspect of Aurora kinase inhibitor development. Here, we review the medicinal chemistry aspect of Aurora kinase inhibitors, with a particular emphasis on the patent literature. Method: The Scifinder® and Delphion® databases were used to search the literature for Aurora kinase inhibitors. Approximately 150 patents and 700 journal references are available, most of them published in the last 5 years. Conclusion/results: Analysis of the literature reveals three common strategies utilized by different groups in developing Aurora kinase inhibitors. These are discussed in detail and could be of use to medicinal chemists in laying out new strategies for developing novel Aurora kinase inhibitors.

AB - Background: Aurora-A, Aurora-B and Aurora-C, members of serine/threonine kinase family, play an important role in mitosis. They are essential for spindle assembly, centrosome maturation, chromosomal segregation and cytokinesis during mitosis. Abnormalities in the mitotic process as a result of overexpression/amplification of Aurora kinase have been linked to genomic instability leading to tumorigenesis. Hence, the use of Aurora kinase small-molecule inhibitors as a potential molecular-targeted therapeutic intervention for cancer is being pursued. Objective: A number of reviews focus on the biology of Aurora kinase; a few focus on the medicinal chemistry aspect of Aurora kinase inhibitor development. Here, we review the medicinal chemistry aspect of Aurora kinase inhibitors, with a particular emphasis on the patent literature. Method: The Scifinder® and Delphion® databases were used to search the literature for Aurora kinase inhibitors. Approximately 150 patents and 700 journal references are available, most of them published in the last 5 years. Conclusion/results: Analysis of the literature reveals three common strategies utilized by different groups in developing Aurora kinase inhibitors. These are discussed in detail and could be of use to medicinal chemists in laying out new strategies for developing novel Aurora kinase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=67649408925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649408925&partnerID=8YFLogxK

U2 - 10.1517/13543770802646949

DO - 10.1517/13543770802646949

M3 - Review article

C2 - 19441907

AN - SCOPUS:67649408925

VL - 19

SP - 321

EP - 356

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 3

ER -